179 related articles for article (PubMed ID: 8829310)
1. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Hellmann K
Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
[TBL] [Abstract][Full Text] [Related]
4. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
6. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
8. [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].
Sauer H
Strahlenther Onkol; 1997 Jan; 173(1):51-2. PubMed ID: 9082586
[No Abstract] [Full Text] [Related]
9. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
11. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
14. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
15. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
[TBL] [Abstract][Full Text] [Related]
17. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
18. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced myocardial injury.
Fujisaki G; Inokuchi C; Murashige N
N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
[No Abstract] [Full Text] [Related]
20. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]